Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644224 | 0.89 | HTT (0.40) | HTTSIGMAR1GRIN1GRIN2BMEN1 | |
| SCHEMBL645657 | 0.88 | HTT (0.40) | HTTSIGMAR1GRIN1GRIN2BMEN1 | |
| SCHEMBL644641 | 0.88 | KMT2A (0.41) | HTTSIGMAR1GRIN1GRIN2BMEN1 | |
| SCHEMBL493666 | 0.79 | MC4R (0.48) | MC4RCCR3IDO1SIGMAR1MEN1 | |
| SCHEMBL10204155 | 0.77 | CACNA2D1 (0.49) | MC4RHTTKMT2ATSHRALDH1A1 | |
| SCHEMBL493226 | 0.74 | C5AR1 (0.39) | HTTGRIN1GRIN2BMEN1KMT2A | |
| SCHEMBL644191 | 0.70 | POLB (0.42) | HTTSIGMAR1MEN1KMT2AKDM4E | |
| SCHEMBL643835 | 0.69 | FKBP1A (0.42) | HTTSIGMAR1MEN1KMT2ATSHR | |
| SCHEMBL493031 | 0.69 | POLB (0.41) | HTTSIGMAR1MEN1KMT2AKDM4E | |
| SCHEMBL644459 | 0.68 | POLB (0.40) | HTTSIGMAR1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119633-B2 | N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases | GRUENENTHAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| EP-2150530-B1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-10-26 | — | — | EP | disclosed |
| EP-2150530-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-02-10 | — | — | EP | disclosed |
| US-20080312231-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| WO-2008131947-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312231-A1 | Substituted Sulfonamide Compounds | SULT2A1, SULT1A1, SCN1A | MC4R 2110/4885HTT 1796/4885CCR3 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.